One dose of aspirin doesn’t fit all

17-Jul-2018 - About one billion people worldwide take regular aspirin, usually to prevent heart attacks or strokes. Researchers have shown that ‘one-dose-fits-all’ use of aspirin to prevent heart attacks, stroke or cancer, is ineffective or harmful in the majority of people, and that a more tailored strategy ...

Circassia Initiates Phase II Trials of Novel Grass and Ragweed Allergy Therapies

Circassia also advances Phase III Plans for cat Allergy T-Cell Vaccine

04-Oct-2010 - Circassia Ltd announced that it has further advanced the clinical development of three of its leading T-cell allergy vaccines. In recent weeks, Circassia has initiated phase II clinical testing of its grass allergy (hayfever) therapy, begun the final stage of phase II testing with its ragweed ...

London Genetics expands its senior advisory team

23-Jul-2010 - London Genetics Limited announced that it has augmented the strength of its team with the appointment of two senior advisers, Professors Stephen DeCherney and Munir Pirmohamed. Stephen DeCherney MD, MPH, is Professor of Medicine at the University of Carolina, and was previously President, Global ...

Q Chip and ARTES Biotechnology announce collaboration to develop sustained release formulations of therapeutic proteins

04-May-2010 - Q Chip Ltd and ARTES Biotechnology GmbH announced that they have signed a Collaborative Agreement to explore the development of a new sustained release formulations of interferon alpha 2a for the treatment of chronic hepatitis B and C. The collaboration aims to improve patient compliance and ...

Welsh shingles drug set for final hurdle

26-Mar-2010 - A new Welsh-developed drug to help alleviate the suffering of shingles could move a step closer for patients if the final stage of testing is given the go-ahead. A new shingles drug (FV-100), discovered by Professor Chris McGuigan's team from Cardiff University's Welsh School of Pharmacy ...

Triple-combo drug shows promise against antiviral-resistant H1N1, UAB researcher says

29-Oct-2009 - An experimental drug cocktail that includes three prescriptions now widely available offers the best hope in developing a single agent to treat drug-resistant H1N1 swine flu, says a virology researcher in the University of Alabama Birmingham (UAB) Division of Pediatric Infectious Diseases. In ...

Vantia Therapeutics’ VA111913 Enters Phase II Proof-of-Concept Trials for Dysmenorrhoea

08-Oct-2009 - Vantia Therapeutics announced that its novel oral small molecule drug for the treatment of dysmenorrhoea (painful menstruation) has entered Phase II proof-of-concept trials. In addition, Vantia announces results of the successful Phase I trial of VA111913, which showed the product candidate to be ...

Pipeline antipsychotic drugs to drive next market evolution

10-Aug-2009 - Antipsychotic pipeline developers have been in the spotlight in recent weeks with the announcement of the FDA approval of Johnson & Johnson’s Invega Sustenna (paliperidone palmitate), FDA panel backing for Schering-Plough’s Saphris (asenapine) and the end of Lundbeck and Solvay’s collaboration ...

Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action

10-Jul-2009 - Funxional Therapeutics Ltd has announced the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs). The Phase I, single ascending dose study was conducted in the ...

PolyTherics Receives Second Patent Allowance in Record Time

07-Jul-2009 - PolyTherics Limited announced that a second patent has been allowed covering the targeted PEGylation of proteins. Issued by the United States Patent Office, this allowance protects PolyTherics’ PEGylation technology in the two largest pharmaceutical markets in the world. This news comes two weeks ...